Lebenslauf

Berufliche Vita

  • 04/2023: Ärztlicher Direktor und Chefarzt, Oberberg Fachklinik Bad Tölz
  • 2015 - 2023: Oberarzt der Tourette-Ambulanz der Klinik für Psychiatrie und Psychotherapie der Universität München (LMU)
  • 2012 - 2023: Oberarzt der Klinik für Psychiatrie und Psychotherapie der Universität München (LMU)
  • 2010 – 2011: Wissenschaftlicher Mitarbeiter der Klinik für Psychiatrie und Psychotherapie der Universität München (LMU)
  • 2004 – 2011: Facharztweiterbildung Psychiatrie und Psychotherapie an der Klinik für Psychiatrie und Psychotherapie der Universität München (LMU)

Studium der Humanmedizin an der Technischen Universität München (TUM), Weill-Cornell-Medical School (NYC, USA), McMaster-University (Hamilton, Kanada); Abschluss 2004

Vernetzung / Fachgesellschaften

  • Arbeitsgemeinschaft Neuropsychopharmakologie (AGNP)
  • Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN)
  • European Society for the Study of Tourette-Syndrome (ESSTS)
  • Deutsche Gesellschaft für Bipolare Störungen (DGBS)
  • International Society for Psychiatric Genetics (ISPG)
  • Deutsche Ärztegesellschaft für Akupunktur (DÄGfA)
  • National Acupuncture Detoxification Association Deutsche Sektion e.V. (NADA)

Auszeichnungen

  • 09/2018: Posterpreis auf dem iSAMS-ICMART-Kongress, München: NADA-auriculoacupuncture as a symptomatic treatment for agitation in people with dementia: a randomized, controlled, rater-blind pilot study
  • 05/2009: Jochen-Gleditsch-Preis (DÄGfA/Elsevier) für besondere Leistungen in der Akupunktur (Summerschool)
  • 10/2006: 1. Posterpreis der Deutschen Gesellschaft für Biologische Psychiatrie (DGBP) auf dem 9. Kongress der DGBP, München: SNAP-25 gene polymorphisms and Weight Gain in Schizophrenic Patients
  • 09/2006: Travel-Award und Guided Poster-Tour auf dem 19. ECNP-Kongress (European College of Neuropsychopharmacology), Paris: SNAP-25 gene polymorphisms and Weight Gain in Schizophrenic Patients
  • 06/2005: Förderpreis der DGBP auf dem 8th World Congress of Biological Psychiatry der WFSBP, Wien: Immune Parameters in patients with depression versus healthy controls during an open-label, placebo-controlled, randomized trial of reboxetine and celecoxib
  • 1997-2004: Stipendiat der Bayerischen Hochbegabtenförderung

Publikationen von Dr. med. Richard Musil

  • Simon MS, Ioannou M, Arteaga-Henríquez G, Wijkhuijs A, Berghmans R, MusilR, Müller N, Drexhage HA. Premature T cell aging in major depression: A double hit by the state of disease and cytomegalovirus infection. 

    Brain Behav Immun Health. 2023 Feb 27;29:100608. Doi: 10.1016/j.bbih.2023.100608 

    Impact factor (2023): 5

  • Müller-Vahl KR, Pisarenko A, Szeijko N, Haas M, Fremer C, Jakubovski E, MusilR, Münchau A, Neuner I, Huys D, van Elst LT, Schröder C, Ringlstetter R, Koch A, Jenz EB, Großhennig A. CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders – Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study. 

    Psychiatry Res. 2023 May; 323:115135. Doi: 10.1016/j.psychres.2023.115135. 

    Impact factor (2023): 11,225

  • Barton BB, Reinhard MA, Goerigk S, Wüstenberg T, MusilR, Ehring T, Jobst A, Dewald-Kaufmann J, Padberg F. Association between the behavioral response during social exclusion and recalled childhood maltreatment. 

    Behav Res Ther. 2023 Jan;160:104232. Doi: 10.1016/j.brat.2022.104232 

    Impact factor (2021): 5,321

  • Reinhard MA, Rek SV, Nenov-Matt T, Barton BB, Dewald-Kaufmann J, Merz K, MusilR, Jobst A, Brakemeier EL, Bertsch K, Padberg F. Association of loneliness and social network size in adulthood with childhood maltreatment: Analyses of a population-based and a clinical simple. 

    Eur Psychiatry. 2022 Sep 5;65(1):e55. Doi: 10.1192/j.eurpsy.2022.2313 

    Impact factor (2022): 7,156

  • Wolf J, Padberg F, Nenov-Matt T, Amann BL, Barton BB, Tang J, Glessner G, Brakemeier EL, Jobst A, MusilR, Reinhard MA. Suicidal behaviors are associated with loneliness and decrease during inpatient CBASP treatment for persistent depressive disorder.

    J Psychiatr Res. 2022 Oct;154:139-144. Doi: 10.1016/j.psychires.2022.07.059

    Impact factor (2022): 5,25

  • Reinhard MA, Popov N, Rek SV, Nenov-Matt T, Barton BB, Jobst A, MusilR, Padberg F. Loneliness is associated with maladaptive schema modes in patients with persistent depressive disorder.

    J Psychiatr Res. 2022 Oct;154:56-60. Doi: 10.1016/j.jpsychires.2022.07.057

    Impact factor (2022): 5,25

  • Heres S, Cordes J, Feyerabend S, Schmidt-Kraepelin C, MusilR, Riedel M, Spellmann I, Langguth B, Landgrebe M, Fran E, Petcu CC, Hahn E, Ta TMT, Matei V, Dehelean L, Papaca I, Leweke FM, van der List T, Tamasan SC, Lang FU, Naber D, Ruhrmann S, Wolff-Menzler C, Juckel G, Ladea M, Stefanescu C, Lautenschlager M, Bauer M, Zamora D, Horowitz M, Davis JM, Leucht S. Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia. 

    Schizoph Bull. 2022 Nov 18;48(6):1273-1283. Doi: 10.1093/schbul/sbac068. 

    Impact factor (2022): 9,306

  • Simon MS, Barton BB, Zagler A, Engl K, Rihs L, Glocker C, MusilR. Lifestyle behaviors, metabolic disturbances, and weight gain in psychiatric inpatients treated with weight gain-associated medication.

    Eur Arch Psychiatry Clin Neurosci. 2022 Jul1 doi: 10.1007/s00406-022-01442-4

    Impact factor (2020): 5,276

  • Sabaß L, Buchenrieder N, Rek SV, Nenov-Matt T, Lange J, Barton BB, MusilR, Jobst A, Padberg F, Reinhard MA. Attachment mediates the link between childhood maltreatment and loneliness in persistent depressive disorder. 

    J Affect. Disord. 2022 Jun 18:S0165-0327(22)00681-4. doi: 10.1016/j.jad.2022.06.021. 

    Impact factor (2021-2022): 4,839

  • Haas M, Jakubovski E, Kunert K, Fremer C, Buddensiek N, Häckl S, Lenz-Ziegenbein M, MusilR, Roessner V, Münchau A, Neuner I, Koch A, Müller-Vahl K. ONLINE-TICS: Internet-Delivered Behavioral Treatment for Patients with Chronic Tic Disorders 

    J Clin Med. 2022 Jan 4;11(1):250. doi: 10.3390/jcm11010250. 

    Impact factor (2020): 4,242

  • Seemüller F, Kolter M, MusilR, Schennach R, Adli M, Bauer M, Brieger P, Laux G, Riedel M, Falkai P, Müller HJ, Padberg F. Chronic vs non-chronic depression in psychiatric inpatient care – Data from a large naturalistic multicenter trial.

    J Affect Disord. 2021 Nov 17;299:73-84. doi: 10.1016/j.jad.2021.11.042.

    Impact factor (2020-2021): 4,839

  • Barton BB, Goerigk S, Wüstenberg T, Dewald-Kaufmann J, Reinhard MA, MusilR, Ehring T, Jobst A, Padberg F. Altered immediate behavioral response to partial social exclusion: A cross-diagnostic study in patients with borderline personality disorder and persistent depressive disorder.

    J Psychiatr Res. 2021 Oct 14; 144: 177-183. doi:10.1016/j.jpsychires.2021.10.005.

    Impact factor (2020): 3,301

  • Simon MS, Burger B, Weidinger E, Arteaga-Henríquez G, Zill P, MusilR, Drexhage HA, Müller N.  Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline - Results From a Randomized Controlled

    Clinical Trial. Front Psychiatry. 2021 Sep 27;12:615261.doi: 10.3389/fpsyt.2021.615261.eCollection 2021.

    Impact factor (2020): 4,157

  • Reinhard MA, Padberg F, Dewald-Kaufmann J, Wüstenberg T, Goerigk S, Barton BB, Zülch A, Brandl L, Windmüller H, Fernandes F, Brunoni AR, MusilR, Jobst A. Sequential Social Exclusion in a Novel Cyberball Paradigm Leads to Reduced Behavioral Repair and Plasma Oxytocin in Borderline Personality Disorder. J Pers Disord. 2021 Aug 24;1-17.

    doi: 10.1521/pedi_2021_35_532.

    Impact factor (2020-2021): 3,132

  • Simon MS, Schiweck C, Arteaga-Henríquez G, Poletti S, Haarman BCM, Dik WA, Schwarz M, Vrieze E, Mikova O, Joergens S, MusilR, Claes S, Baune BT, Leboyer M, Benedetti F, Furlan R, Berghmans R, de Wit H, Wijkhuijs A, Arolt V, Müller N, Drexhage HA. Monocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Dec 20;111:110391.

    doi: 10.1016/j.pnpbp.2021.110391. Epub 2021 Jun 23.

    Impact factor (2020): 5,067

  • Konvalin F, Grosse-Wentrup F, Nenov-Matt T, Fischer K, Barton BB, Goerigk S, Brakemeier E-L, MusilR, Jobst A, Padberg F, Reinhard MA. Borderline Personality Features in Patients With Persistent Depressive Disorder and Their Effect on CBASP Outcome. Front Psychiatry. 2021 Mar 12;12:608271.

    doi: 10.3389/fpsyt.2021.608271. eCollection 2021.

    Impact factor (2020): 4,157

  • Kai F Fischer, Simon MS, Elsner J,  Dobmeier J,  Dorr J,  Blei L,  Zill P, Obermeier M,  MusilR. Assessing the links between childhood trauma, C-reactive protein and response to antidepressant treatment in patients with affective disorders. Eur Arch Psychiatry Clin Neurosci. 2021 Oct;271(7):1331-1341.

    doi: 10.1007/s00406-021-01245-z. Epub 2021 Mar 17.

    Impact factor (2020): 5,270

  • Dewald-Kaufmann JF, Wüstenberg T, Barton BB, Goerigk S, Reinhard MA, MusilR, Werle J, Falkai P, Jobst A, Padberg F. Dynamics of the immediate behavioral response to partial social exclusion.

    Sci Rep. 2021 Jan 20;11(1):1853. Doi: 10.1038/s41598-020-80039-0

    Impact factor (2019): 4,379

  • Nenov-Matt T, Barton BB, Dewald-Kaufmann J, Goerigk S, Rek S, Zentz K, MusilR, Jobst A, Padberg F, Reinhard MA. Loneliness, Social Isolation and Their Difference: A Cross-Diagnostic Study in Persistent Depressive Disorder and Borderline Personality Disorder

    Front Psychiatry. 2020 Dec 17;11:608476. Doi: 10.3389/fpsyt.2020.608476

    Impact factor (2020): 4,157

  • Schennach R, Riedel M, Obermeier M, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Seemüller F, Spellmann I, MusilR, Möller HJ. What Happens With Schizophrenia Patients After Their Discharge From Hospital? Results on Outcome and Treatment From a “Real-World” 2-year Follow-Up Trial

    Eur Arch Psychiatry Clin Neurosci 2019 Aug 28[Online ahead of print]. doi:  10.1007/s00406-019-01055-4

    Impact factor (2019): 3,192

  • Barton B, Zagler A, Engl K, Rihs L, Musil R. Prevalence of obesity, metabolic syndrome, diabetes and risk of cardiovascular disease in a psychiatric inpatient sample: Results of the Metabolism in Psychiatry (MiP) Study

    Eur Arch Psychiatry Clin Neurosci 2019 Jul 13[Online ahead of print]. doi: 10.1007/s00406-019-01043-8

    Impact factor (2019): 3,192

  • Arteaga-Henriquez G, Simon MS, Burger B, Weidinger E, Wijkhuijs A, Arolt V, Birkenhager TK, MusilR, Müller N, Drexhage HA. Low grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients. A systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME consortium

    Frontiers Psychiatry 2019 Jul 9, 10, 458. doi: 10.3389/fpsyt.2019.00458,

    Impact factor (2018): 3,532

  • Schennach R, Obermeier M, Spellmann I, Seemüller F, MusilR, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Bauer M, Adli M, Zeiler J, Bender W, Kronmüller KT, Ising M, Brieger P, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ, Riedel M. Remission in schizophrenia – What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression

    Schizophr Res. 2019 May 25, pii: S0920-9964(19)30155-0. doi: 10.1016/j.schres.2019.04.022.

    Impact factor (2018): 3,958

  • Kirchner SK, Ozkan S, MusilR, Spellmann I, Kannayian N, Falkai P, Rossner M, Papiol S. Polygenic analysis suggests the involvement of calcium signaling in executive function in schizophrenia Patients

    Eur Arch Psychiatry Clin Neurosci. 2018 Dec 7. Doi: 10.1007/s00406-018-0961-8.

    Impact factor (2017): 3,617

  • Schennach R, Riedel M, Spellmann I, MusilR, Obermeier M, Jäger M, Bottlender R, Schaumss M, Laux G, Möller HJ. Comparing schizophrenia patients with a predicted high/low risk of nonresponse receiving treatment with ziprasidone and haloperidol: a randomized-controlled study

    Pharmacopsychiatry. 2018 Sep 20. doi: 10.1055/a-0669-9461. [Epub ahead of print]

    Impact factor (2017): 2,064

  • MusilR, Seemüller F, Meyer S, Spellmann I, Adli M, Bauer M, Kronmüller K-T, Brieger P, Laux G, Bender W, Heuser I, Fisher R, Gaebel W, Schennach R, Möller H-J, Riedel M. Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder

    Int J Methods Psychiatr Res. 2018 Mar;27(1).

    doi: 10.1002/mpr.1569. Epub 2017 Jun 14.

    Impact factor (2017): 2,500

  • Spellmann I, Reinhard MA, Veverka D, Zill P, Obermeier M, Dehning S, Schennach R, Müller N, Riedel M, MusilR. QTc prolongation in short-term treatment of schizophrenia patients: effects of different antipsychotics and genetic factors.

    Eur Arch Psychiatry Clin Neurosci. 2018 Jun;268(4):383-390. doi: 10.1007/s00406-018-0880-8. Epub 2018 Feb 10.

    Impact factor (2017): 3,617

  • Schennach R, Obermeier M, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter, J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Spellmann I, MusilR, Möller HJ, Riedel M. Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder – When, Who, and How?

    Pharmacopsychiatry. 2017 Jul;50(4):136-144. doi: 10.1055/s-0043-106436. Epub 2017 May 15.

    Impact factor (2017): 2,064

  • Spellmann I, Riedel M, Städtler J, Zill P, Obermeier M, Cerovecki A, Dehning S, Schennach R, Epple M, Opgen-Rhein M, Müller N, Bondy B, Möller H-J, MusilR. Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment

    Cogn Neuropsychiatry. 2017 Jul;22(4):280-297. doi: 10.1080/13546805.2017.1322502. Epub 2017 May 4.

    Impact factor (2017): 1,329

  • Krause D, Myint AM, Schuett C, MusilR, Dehning S, Cerovecki A, Riedel M, Arolt V, Schwarz MJ, Müller N. High Kynurenine (a Tryptophan Metabolite) Predicts Remission in Patients with Major Depression to Add-on Treatment with Celecoxib.

    Front Psychiatry. 2017 Feb 13;8:16 doi: 10.3389/fpsyt.2017.00016. eCollection 2017.

    Impact factor (2017): 2,857

  • Spellmann I, Schennach R, Seemüller F, Meyer S, MusilR, Jäger M, Schmauß M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Bauer M, Adli M, Zeiler J, Bender W, Kronmüller KT, Ising M, Brieger P, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Riedel M, Möller HJ. Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies.

    Eur Arch Psychiatry Clin Neurosci. 2017 Jun;267(4):303-313. doi: 10.1007/s00406-016-0741-2. Epub 2016 Oct 26.

    Impact factor (2017): 3,617

  • Schennach R, Möller HJ, Obermeier M, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, MusilR, Spellmann I, Riedel M. Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methods.

    Int J Methods Psychiatr Res. 2016 Mar;25(1):3-11. doi: 10.1002/mpr.1476. Epub 2015 Jul 14.

    Impact factor (2016): 3,176

  • Schennach R, Riedel M, Obermeier M, Spellmann I, MusilR, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ. What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial.

    Eur Arch Psychiatry Clin Neurosci. 2015 Mar;265(2):107-16.

    doi: 10.1007/s00406-014-0528-2. Epub 2014 Sep 27.

    Impact factor (2015): 4,113

  • Seemüller F, Meier S, Obermeier M, MusilR, Bauer M, Adli M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Riedel M, Falkai P, Möller H-J. Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors.

    doi: 10.1007/s00406-014-0495-7. Epub 2014 Mar 4.

    Impact factor (2014): 3,35

    Eur. Arch. Psychiatry Clin. Neurosci. (2014) 264, 567–575.

  • Spellmann I, Rujescu D, Musil R, Meyer S, Giegling I, Genius J, Zill P, Dehning S, Cerovecki , Seemüller F, Schennach R, Hartmann AM, Schäfer M, Müller N, Möller H-J, Riedel M. Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients.

    Prog. Neuropsychopharmacol. Biol. Psychiatry 2014 Jun 3;51:190-5. doi: 10.1016/j.pnpbp.2014.02.006. Epub 2014 Feb 25

    Impact factor (2014): 3,7

  • Musil R, Zill P, Seemüller F, Bondy B, Obermeier M, Spellmann I, Bender W, Adli M, Heuser I, Zeiler J, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller H-J, Riedel M. No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression.

    Eur Arch Psychiatry Clin Neurosci. 2013 Aug;263(5):405-12. doi: 10.1007/s00406-012-0364-1. Epub 2012 Sep 11.

    Impact factor (2014): 3,55

  • MusilR, Zill P, Seemüller F, Bondy B, Meyer S, Spellmann I, Bender W, Adli M, Heuser I, Fisher R, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller H-J, Riedel M. Genetics of emergent suicidality during antidepressive treatment--data from a naturalistic study on a large sample of inpatients with a major depressive episode.

    Eur Neuropsychopharmacol. 2013 Jul;23(7):663-74. doi: 10.1016/j.euroneuro.2012.08.009. Epub 2012 Oct 11.

    Impact factor (2013): 5,39

  • Seemüller F, Lewitzka U, Bauer M, Meyer S, MusilR, Schennach R, Riedel M, Doucette S, Möller HJ. The Relationship of Akathisia with Treatment Emergent Suicidality among Patients with First-Episode Schizophrenia Treated with Haloperidol or Risperidone.

    Pharmacopsychiatry. 2012 Nov;45(7):292-6. doi: 10.1055/s-0032-1309004. Epub 2012 May 21

    Impact Factor (2012): 2,071

  • Seemüller F, Schennach R, Mayr A, MusilR, Jäger M, Maier W, Klingenberg S, Heuser I, Klosterkötter J, Gastpar M, Schmitt A, Schlösser R, Schneider F, Ohmann C, Lewitzka U, Gaebel W, Möller H-J, Riedel M, German Study Group on First-Episode Schizophrenia. Akathisia and suicidal ideation in first-episode schizophrenia.

    J. Clin. Psychopharmacol. (2012) 32, 694–698. doi:10.1097/JCP.0b013e3182677958

    Impact factor (2012): 3,51

  • Schennach, R., Meyer, S., Seemüller, F., Jäger, M., Schmauss, M., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L.G., Gaebel, W., Klosterkötter, J., Heuser, I., Maier, W., Lemke, M.R., Rüther, E., Klingberg, S., Gastpar, M., Musil R., Möller, H.-J., Riedel, M. Response trajectories in “real-world” naturalistically treated schizophrenia patients.

    Schizophr Res. 2012 Aug;139(1-3):218-24. doi: 10.1016/j.schres.2012.05.004. Epub 2012 Jun 2.

    Impact factor (2012): 4,59

  • Schennach R, Riedel M, MusilR, Möller HJ. Treatment Response in First-episode Schizophrenia. Clin Psychopharmacol Neurosci. 2012 Aug;10(2):78-87. doi:

    10.9758/cpn.2012.10.2.78. Epub 2012 Aug 31.

    Impact factor (2012): 4,59

  • Spellmann I, Riedel M, Schennach R, Seemüller F, Obermeier M, MusilR, Schmauß M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ. One-year functional outcomes of naturalistically treated patients with schizophrenia.

    Psychiatry Res. 2012 Aug 15;198(3):378-85. doi: 10.1016/j.psychres.2011.12.047. Epub 2012 Mar 14.

    Impact Factor (2012): 2,524

  • Schennach R, Zill P, Obermeier M, Hauer D, Dehning S, Cerovecki A, Opgen-Rhein M, MusilR, Spellmann I , Matz J, Krause D, Seemüller F, Müller N, Möller H-J, Bondy B, Riedel M. The CNR1 gene in depression and schizophrenia - is there an association with early improvement and response?

    Psychiatry Res. 2012 Mar 30;196(1):160. doi: 10.1016/j.psychres.2011.11.021. Epub 2012 Feb 25.

    Impact factor (2012): 4,06

  • MusilR, Schwarz MJ, Riedel M, Dehning S, Cerovecki A, Spellmann I, Arolt V, Müller N. Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression--no influence of celecoxib treatment.

    J Affect Disord. 2011 Nov;134(1-3):217-25. doi: 10.1016/j.jad.2011.05.047. Epub 2011 Jun 17.

    Impact Factor (2010): 3,740

  • Riedel M, Spellmann I, Schennach-Wolff R, Obermeier M, Musil R. The RSM-scale: a pilot study on a new specific scale for self- and observer-rated quality of life in patients with schizophrenia.

    Qual Life Res. 2011 Mar;20(2):263-72. doi: 10.1007/s11136-010-9744-z. Epub 2010 Oct 5.

    Impact Factor (2010): 2,376

  • Riedel M, Severus E, Schennach-Wolff R, MusilR, Spellmann I, Oppolzer B, Möller HJ, Köhler J, Seemüller F, (2011). Effectiveness of quetiapine in outpatients with schizophrenia assessed under "real-life" conditions: a German clinical-practice evaluation programme.

    J Clin Psychopharmacol. 2011 Feb;31(1):120-2.

    doi: 10.1097/JCP.0b013e3182061184.

    Impact factor (2010): 4,86

  • Spellmann I, Rujescu D, Musil R, Mayr A, Giegling I, Genius J, Zill P, Dehning S, Opgen-Rhein M, Cerovecki A, Hartmann AM, Schäfer M, Bondy B, Müller N, Möller HJ, Riedel M. Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients.

    J Psychiatr Res. 2011 Feb;45(2):234-41. doi: 10.1016/j.jpsychires.2010.06.004. Epub 2010 Jul 3.

    Impact Factor (2010): 3,723

  • Müller N, Krause D, Dehning S, MusilR, Schennach-Wolff R, Obermeier M, Möller HJ, Klauss V, Schwarz MJ, Riedel M. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment.

    Schizophr Res. 2010 Aug;121(1-3):118-24. doi: 10.1016/j.schres.2010.04.015. Epub 2010 May 31.

    Impact Factor (2010): 4,458

  • Seemüller F, Riedel M, Obermeier M, Bauer M, Adli M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Dichgans E, Bottländer R, MusilR, Möller HJ, (2010). Outcomes of 1014 naturalistically treated inpatients with major depressive episode.

    Eur Neuropsychopharmacol. 2010 May;20(5):346-55. doi: 10.1016/j.euroneuro.2009.11.011. Epub 2010 Jan 22.

    Impact factor (2010): 4,20

  • Riedel M, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, Opgen-Rhein M, Matz J, Seemüller F, Obermeier M, Engel RR, Müller N, Möller HJ, Spellmann I, (2010). Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone.

    Hum Psychopharmacol. 2010 Mar;25(2):116-25. doi: 10.1002/hup.1101.

    Impact factor (2010): 2,60

  • Riedel M, Spellmann I, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, Opgen-Rhein M, Matz J, Seemüller F, Obermeier M, Severus E, Engel RR, Müller N, Möller HJ, (2010). Effect of aripiprazole on cognition in the treatment of patients with schizophrenia.

    Pharmacopsychiatry. 2010 Mar;43(2):50-7. doi: 10.1055/s-0029-1239539. Epub 2009 Dec 10.

    Impact factor (2010): 2,20

  • Dehning S, Müller N, Matz J, Bender A, Kerle I, Benninghoff J, Musil R, Spellmann I, Bondy B, Möller HJ, Riedel M, Zill P. A genetic variant of HTR2C may play a role in the manifestation of Tourette syndrome.

    Psychiatr Genet. 2010 Feb;20(1):35-8. doi: 10.1097/YPG.0b013e32833511ce.

    Impact Factor (2010): 2,696

 

Kumulativer impact factor Originalarbeiten: 224,844

In gelisteten peer-reviewed Journals

  • Paschou P, Jin Y, Müller-Vahl K, Möller HE, Rizzo R, Hoekstra PJ, Roessner V, Mol Debes N, Worbe Y, Hartmann A, Mir P, Cath D, Neuner I, Eichele H, Zhang C, Lewandowska K, Munchau A, Verrel J, Musil R, Silk TJ, Hanlon CA, Bihun ED, Brandt V, Dietrich A, Forde N, Ganos C, Greene DJ, Chu C, Grothe MJ, Hershey T, Janik P, Koller JM, Martin-Rodriguez JG, Müller K, Palmucci S, Prato A, Ramkiran S, Saia F, Szejko N, Torrecuso R, Tumer Z, Uhlmann A, Veselinovic T, Wolanczyk T, Zouki JJ, Jain P, Topaloudi A, Kaka M, Yang Z, Drineas P, Thomopoulos SI, White T, Veltman DJ, Schmaal L, Stein DJ, Buitelaar J, Franke V, van den Heuvel O, Jahanshad N, Thompson PM, Black KJ. Enhancing neuroimaging genetics through meta-analysis for Tourette syndrome (ENIGMA-TS): A worldwide platform for collaboration

    Front Psychiatry. 2022 Aug 18;13:958688. Doi:3389/fpsyt.2022.958688

    Impact factor (2021): 5,435

  • Kalman JL, Burkhardt G, Adorjan K, Barton BB, De Jonge S, Eser-Valeri D, Falter-Wagner CM, Heilbronner U, Jobst A, Keeser D, Koenig C, Koller G, Koutsouleris N, Kurz C, Landgraf D, Merz K, MusilR, Nelson AM, Padberg F, Papiol S, Pogarell O, Perneczky R, Raabe F, Reinhard MA, Richter A, Rüther T, Simon MS, Schmitt A, Slapakova L, Scheel N, Schüle C, Wagner E, Wichert SP, Zill P, Falkai P, Schulze TG, Schulte EC. Biobanking in everyday clinical practice in psychiatry – The Munich Mental Health Biobank.

    Front Psychatr. 2022 Jul 22;13:934640. Doi: 10.3389/fpsyt.2022.934640

    Impact factor (2021): 5,435

  • Bousman CA, Bengesser SA, Aitchison KJ, Amare AT, Aschauer H, Baune BT, Asl BB, Bishop JR, Burmeister M, Chaumette B, Chen LS, Cordner ZA, Deckert J, Degenhardt F, DeLisi LE, Folkersen L, Kennedy JL, Klein TE, Mc Clay JL, McMahon FJ, MusilR, Saccone NL, Sangkuhl K, Stowe RM, Tan EC, Tiwari SAK, Zai CC, Zai G, Zhang J, Gaedigk A, Müller DJ. Review and Consensus on Pharmacogenomic Testing in Psychiatry

    Pharmacopsychiatry. 2021 Jan;54(1):5-17. doi: 10.1055/a-1288-1061. Epub 2020 Nov 4

    Impact Factor (2019): 5,788

  • Barton BB, Segger F, Fischer K, Obermeier M, MusilR. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis

    Expert Opin Drug Saf. 2020 Mar;19(3):295-314. doi: 10.1080/14740338.2020.1713091. Epub 2020 Mar 12

    Impact Factor (2019): 3,320

  • Reinhard MA, Dewald-Kaufmann J, Wüstenberg T, MusilR, Barton B, Jobst A, Padberg F. The Vicious Circle of Social Exclusion and Psychopathology; A Systematic Review of Experimental Ostracism Research in Psychiatric Disorders

  • Eur Arch Psychiatry Clin Neurosci 2019 Oct 4[Online ahead of print].

    DOI: 10.1007/s00406-019-01074-1

    Impact Factor (2019): 3,192

  • Schnell J, Weidinger E, MusilR. Patienten mit Tic-Störungen: weit bekannt, doch unterversorgt / Patients with tic disorders: widely known, yet underserved

    Fortschr Neurol Psychiatr 2019; 87: 577–589. doi: 10.1055/a-0996-0944

    Impact Factor (2019): 0,635

  • Reedtz C, van Doesum K, Signorini G, Lauritzen C, van Amelsvoort T, van Santvoort F, Young AH, Conus P, Musil R, Schulze T, Berk M, Stringaris A, Piché G, de Girolamo G. Promotion of Wellbeing for children of Parents With Mental Illness: A Model Protocol for Research and Intervention

    Front Psychiatry, 2019 Sep 6, 10, 606. doi: 10.3389/fpsyt.2019.00606

    Impact Factor (2017): 3,532

  • Musil R, Spellmann I. Pharmacogenetics and cognitive symptoms in schizophrenia patients treated with antipsychotics

    Pharmacogenomics. 2018 Aug 1;19(12):927-930. doi: 10.2217/pgs-2018-0083. Epub 2018 Jul 20. 

    Impact Factor (2017): 2,302

  • Musil R, Obermeier M, Russ P, Hamerle M. Weight gain and antipsychotics: a drug safety review.

    Expert Opin Drug Saf. 2015 Jan;14(1):73-96. doi: 10.1517/14740338.2015.974549. Epub 2014 Nov 15.

    Impact Factor (2015): 2,264

  • Cerovecki, A., Musil R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., Riedel, M. (2013). Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 27, 545–572.

    doi:10.1007/s40263-013-0079-5

    Impact factor (2014): 4,38

  • Berger M, Musil R, Seemüller F, (2014). [Long-term treatment of bipolar disorder]

    Fortschr Neurol Psychiatr. 2014 Jun;82(6):346-58; quiz 359-60. doi: 10.1055/s-0034-1366575. Epub 2014 Jun 5.

    Impact factor (2013): 0,629

  • Seemüller F, Berger M, MusilR, Severus E, Dittmann S, Born C, Schaub A, Dargel S, Grunze H, (2013). [The challenge of treating bipolar outpatients].

    Fortschr Neurol Psychiatr. 2013 May;81 Suppl 1:S35-9. doi: 10.1055/s- 0033-1335275. Epub 2013 May 16. German.

    Impact factor (2013): 0,762

  • Schennach R, MusilR, Möller HJ, Riedel M. Functional outcomes in schizophrenia: employment status as a metric of treatment outcome.

    Curr Psychiatry Rep. 2012 Jun;14(3):229-36. doi: 10.1007/s11920-012-0261-3.

    Impact factor (2013): 3,238

  • Seemüller F, Möller HJ, Dittmann S, Musil R. Is the efficacy of psychopharmacological drugs comparable to the efficacy of general medicine medication?

    BMC Med. 2012 Feb 15;10:17. doi: 10.1186/1741-7015-10-17.

    Impact factor (2013): 6,1

 

Kumulativer impact factor Übersichtsarbeiten: 47,012

  • Behler N, Leitner B, Mezger E, Weidinger E, Musil R, Blum B, Kirsch B, Wulf L, Löhrs L, Winter C, Padberg F, Palm U. Cathodal tDCS over motor cortex does not improve

    Tourette Syndrome: Lessons learned from a case seriesFront. Behav. Neurosci. 2018; 12:194. doi: 10.3389/fnbeh.2018.00194

    Impact factor (2017): 3.138

  • Richieri R, Blackman G, Musil R, Spatola, Cavanna AE, Lancon C, Régis J. Positive clinical effects of gamma knife capsulotomy in a patient with deep brain stimulation-refractory Tourette Syndrome and Obsessive Compulsive Disorder.

    Clin Neurol Neurosurg. 2018 Jul;170:34-37. doi: 10.1016/j.clineuro.2018.04.018. Epub 2018 Apr 26

    Impact factor (2017): 1.736

  • Nowidi K, Kunisch R, Bouna-Pyrrou P, Meißner D, Hennig-Fast K, Weindl A, Förster S, Neuhann TM, Falkai P, Berger M, Musil R. [The White man's burden - a case study caught between bipolar affective disorder and Huntington's disease].

    Fortschr Neurol Psychiatr. 2013 Jun;81(6):337-45. doi: 10.1055/s-0033-1335040. Epub 2013 Apr 23. German

    Impact factor (2013): 0.762

 

Kumulativer impact factor Fallberichte: 5,636

  • Musil R, Hofer E-M, Colling C. Akupunktur in der Psychiatrie - Chancen und Grenzen

    Zeitschrift für Komplementärmedizin 2021; 13(06): 36-40 doi: 10.1055/a-1663-5248

  • Barton BB, Simon MS, Glocker C, MusilR. Was tun, wenn das Körpergewicht ansteigt?

    InFo Neurologie & Psychiatrie 2020 Dec 22(12) doi: 10.1007/s15005-020-1555-3

  • Musil R, Falkai P. Neuro-psychopharmacotherapy and the Differential Diagnostic Approaches in Europe

    Kapitel in “NeuroPsychopharmacotherapy” doi: 10.1007/978-3-319-56015-1_367-1

  • Barton B, MusilR. Posttraumatische Belastungsstörung

    Deutsche Zeitschrift für Akupunktur 2019 Feb. 62(1):24-27 doi: 10.1007/s42212-018-0128-6

  • MusilR. Tourette Syndrom - Aktuelle Therapieansätze

    CliniCum neuropsy 2018, 4/18; 2-4

  • Schnell JML, Weidinger E, Musil R. Patienten mit Tics [Patients with tics]

    MMW Fortschr Med. 2018 Sep;160(15):47-50. doi: 10.1007/s15006-018-0886-1. Review.

  • MusilR. Verbesserte Fähigkeit zur Emotionsregulation.

    InFo Neurologie & Psychiatrie 2017 Aug., Vol. 19, Issue 7-8, pp 24-24 Journal Club

  • Anetzberger F, Meinhardt J, MusilR. Dialektisch-behaviorale Therapie – eine Übersicht

    Ärztliche Psychotherapie 2017 3, Schattauer GmbH, Schwerpunkt

  • Schottdorf J, MusilR. Psychische Traumatherapie mit akupunkturgestützter Exposition in drei Schritten.

    Deutsche Zeitschrift für Akupunktur 2017 Jan. 60(4):6-12 DOI: 10.1016/S0415-6412(17)30113-3 Innovation

  • Kloiber S, MusilR. Akupunktur bei psychiatrischen Erkrankungen – Literaturüberblick und Entwicklungsmöglichkeiten. Teil 3: Somatoforme Störungen, Posttraumatische Störungen, bipolare Störungen, Zwangserkrankungen, Schlafstörungen, Schizophrenie.

    Deutsche Zeitschrift für Akupunktur 2016;59(1):6-9.

  • Musil R. Chinesische Medizin und Psychotherapie – ein Blick nach vorn.

    Deutsche Zeitschrift für Akupunktur 2016;59(1):10. Kommentar

  • Musil R. Rapid Onset of the Effects of Combined Selective Serotonin Reuptake Inhibitors and Electroacupuncture on Primary Depression: A Meta-Analysis

    Deutsche Zeitschrift für Akupunktur 2016 Dec. 59(3):27-29. DOI: 10.1016/S0415-6412(16)30084-4 Journal Club

  • Kloiber S, Musil R. Akupunktur bei psychiatrischen Erkrankungen - Literaturüberblick und Entwicklungsmöglichkeiten. Teil 2: Depressive Erkrankungen (unipolare Depression, schwangerschaftsassoziierte depressive Störungen, Poststroke Depression), Angststörungen. Deutsche Zeitschrift für Akupunktur 2016;59,1:6-11

  • Musil R, Kloiber S. Akupunktur bei psychiatrischen Erkrankungen- Literaturüberblick und Entwicklungsmöglichkeiten. Teil 1: Demenzerkrankungen, substanzbedingte Erkrankungen, Essstörungen, Persönlichkeitsstörungen, Aufmerksamkeitsdefizit-/Hyperaktivitätssyndrom. Deutsche Zeitschrift für Akupunktur 2016;59,1:7–13

  • Palm U, Musil R, Ienciu M, Jakovljevic M, Kapfhammer HP, Kasper S, Keck ME, Langguth B, Lanzenberger R, Meisenzahl E, Möller HJ, Müller N, Nedopil N, Sartorius N, Schöny W, Falkai P. The 26th Danube Symposium of Psychiatry: Psychiatry - ready for the future?

    Psychiatr Danub. 2016 Mar;28(1):95-6

  • Musil R. Weight gain as a consequence of treatment with antipsychotics - What do we know and what can we do?

    Die Psychiatrie 2015; 12: 262–268

  • Musil R, Krieger I. 1. DÄGfA-Symposium „Akupunktur und Psychiatrie“ überwindet Grenzen und setzt neue Akzente

    Deutsche Zeitschrift für Akupunktur 2015 Dec. (58) 1:48-49 DOI: 10.1016/S0415-6412(15)60020-0

  • Schennach R, Musil R, Möller HJ, Riedel M. Functional outcomes in schizophrenia: employment status as a metric of treatment outcome.

    Curr Psychiatry Rep. 2012 Jun;14(3):229-36. Review

    Impact Factor (2012): 2,711

  • Musil R. The safety, acceptability, and effectiveness of acupuncture as an adjunctive treatment for acute symptoms in bipolar disorder.

    Deutsche Zeitschrift für Akupunktur 2011 (54) 4:21-22 Journal Club

  • Riedel M, Musil R, Seemüller F, Spellmann I, Möller HJ, Schennach-Wolff R. Safety evaluation of zotepine for the treatment of schizophrenia.

    Expert Opin Drug Saf. 2010; Jul;9(4):659-66. Review

    Impact Factor (2010): 2,645

  • Riedel M, Spellmann I, Musil R, Seemüller F, Möller HJ, Schennach-Wolff R. Prädiktoren der Akutbehandlung in der Schizophrenie.

    Ärztliche Praxis Neurologie/Psychiatrie 02/2010

  • Bondy B, Spellmann I, Musil R, Zill P, Müller N, Möller HJ, Riedel M. Die Bedeutung der Pharmakogenetik für die antipsychotische Therapie.

    In „Schizophrenie - Zukunftsperspektiven in Klinik und Forschung“. Hrsg. Möller, Müller (2010) SpringerWienNewYork

  • Schwarz MJ, Musil R, Spellmann I, Opgen-Rhein M, Jurgeleit F, Sirch S, Sterz S, Zach J, Riedel M. Therapeutisches Drug-Monitoring neuerer atypischer Antipsychotika.

    In „Schizophrenie - Zukunftsperspektiven in Klinik und Forschung“. Hrsg. Möller, Müller (2010) SpringerWienNewYork

  • Riedel M, Seemüller F, Musil R, Spellmann I, Möller HJ, Schennach-Wolff R. Early Improvement and Its Predictive Validity in First-Episode Schizophrenia Patients.

    In “Handbook of Schizophrenia Spectrum Disorders, Volum III”. Hrsg. Ritsner, M.S. (2011) Springer Science+Business Media B.V.

  • Schennach-Wolff R, Seemüller F, Musil R, Spellmann I, Möller HJ, Riedel M. Suicidality and Outcome in Schizophrenia.

    In “Handbook of Schizophrenia Spectrum Disorders, Volum III”. Hrsg. Ritsner, M.S. (2011) Springer Science+Business Media B.V.

  • Schennach R, Musil R, Riedel M, Möller HJ. Current developments in the treatment of schizophrenia - a short review.

    Hospital Healthcare Europe: current developments in the treatment of schizophrenia, (2012)

  • Musil R. Praxisjahr für Mediziner im Ausland

    Deutsche Zeitschrift für Akupunktur 2010 Dec. (53) 1:72-72

Kumulativer impact factor sonstige Beiträge, Übersichtsarbeiten und Buchbeiträge: 5,356

  • Cath DC, Hedderly T, Ludolph AG, Stern JS, Murphy T, Hartmann A, Czernecki V, Robertson MM, Martino D, Munchau A, Rizzo R; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part I: assessment

    Eur Child Adolesc Psychiatry. 2011 Apr;20(4):155-71. Erratum in: Eur Child AdolescPsychiatry. 2011 Jul;20(7):377.

    Impact Factor (2010): 1,622

  • Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, Strand G, Stern JS, Termine C, Hoekstra PJ; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment.

    Eur Child Adolesc Psychiatry. 2011 Apr;20(4):173-96. Erratum in: Eur Child Adolesc Psychiatry. 2011 Jul;20(7):377.

    Impact Factor (2010): 1,622

  • Verdellen C, van de Griendt J, Hartmann A, Murphy T; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions.

    Eur Child Adolesc Psychiatry. 2011 Apr;20(4):197-207. Erratum in: Eur Child Adolesc Psychiatry. 2011 Jul;20(7):377.

    Impact Factor (2010): 1,622

  • Müller-Vahl KR, Cath DC, Cavanna AE, Dehning S, Porta M, Robertson MM, Visser-Vandewalle V; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation.

    Eur Child Adolesc Psychiatry. 2011 Apr;20(4):209-17. Erratum in: Eur Child Adolesc Psychiatry. 2011 Jul;20(7):377.

    Impact Factor (2010): 1,622

Kumulativer impact factor Leitlinien: 6,488

107 (27 Erst- oder Letztautorschaften, davon 11 bei Originalia)

Kumulativer Impact: 289,436

 

  • Recommendations: 92
  • h-index: 28 (ResearchGate)
  • h-index: 30 (GoogleScholar)
  • i10-index: 44
  • Citations (Research Gate): 2940
  • Research Interest: 1489
  • Reads: 16.192
28
H-Index
2940
Anzahl der Zitierungen
107
Publikationen